Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARADIGM CORP. ARDM -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (191)	3/30/2004 11:52:26 AM
From: idler	Read Replies (1) \| Respond to of 255

This may or may not mean anything - I mentioned inhalable insulin to my family physician, and he is very skeptical it will ever be brought to market - he thinks it's too hard to precisely regulate the dosage by inhalation (e.g., if someone has a cold and can't breath properly) and injection isn't such a hardship or inconvenience. I don't know what to make of it - not being an expert.

To: tuck who wrote (191)	4/30/2004 8:40:14 AM
From: rkrw	Read Replies (1) \| Respond to of 255

Was todays ardm announcement good news or bad news? Here's yet another inhaled insulin company. Isn't Mankind the name of a world wrestler? No doubt named after someone named Mann. Add it to the list of cheesy biotech names :-) Reuters UPDATE - Biopharmaceutical firm MannKind files for IPO Friday April 30, 8:34 am ET (Adds details) WASHINGTON, April 30 (Reuters) - MannKind Corp., a biopharmaceutical firm focused on treatments for diabetes, cancer and autoimmune diseases, on Friday filed with the U.S. Securities and Exchange Commission (News - Websites) to go public. The Valencia, California-based company filed a preliminary offering document for as much as $86.25 million in common stock but did not specify the number of shares or the price for the IPO, as those details are expected in future filings. UBS Investment Bank, Piper Jaffray, Wachovia Securities, Jefferies & Co. Inc. and Harris Nesbitt Gerard are listed in the prospectus as the underwriters. It is seeking a Nasdaq listing under the symbol "MNKD." The company said it plans to use the proceeds from the IPO for developing its dry powder insulin that is inhaled, working capital and other general corporate purposes.